<DOC>
	<DOCNO>NCT01165177</DOCNO>
	<brief_summary>The purpose observer-blind study evaluate efficacy , safety immunogenicity GSK Biologicals ' candidate Herpes Zoster ( HZ ) vaccine adult age ≥ 50 year . Two study [ ZOSTER-006 ( NCT01165177 ) ZOSTER-022 ( NCT01165229 ) ] conduct concurrently evaluate efficacy GSK1437173A vaccine . A pooled analysis data study combine conducted contingent study achieve objective . The protocol post study ZOSTER-022 also deal outcome measure relate pooled analysis .</brief_summary>
	<brief_title>Study Evaluate Efficacy , Safety Immunogenicity GSK Biologicals ' Herpes Zoster ( HZ ) Vaccine GSK1437173A Adults Aged 50 Years Older</brief_title>
	<detailed_description>This protocol summary update follow Protocol Amendment 4 change study objectives endpoint analyse objective 2 step . Step 1 include analysis follow objective ZOSTER-006 ( NCT01165177 ) : HZ VE objectives reactogenicity/safety immunogenicity objective . At step 2 , objective study ZOSTER-006 ( NCT01165177 ) analyze . Objectives already analyzed step 1 re-analyzed ( confirmatory descriptive case inferential analysis step 1 descriptive analysis otherwise ) . At step 2 , pool analysis study ZOSTER-006 ( NCT01165177 ) ZOSTER-022 ( NCT01165229 ) plan ; overall PHN VE subject ≥ 70 YOA , pre-specified endpoint analyze .</detailed_description>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol ; Written inform consent obtain subject ; A male female age 50 year old time first vaccination ; Female subject nonchildbearing potential may enrol study ; For study population , nonchildbearing potential define current tubal ligation , hysterectomy , ovariectomy postmenopause . OR Female subject childbearing potential may enrol study , subject practice adequate contraception 30 day prior vaccination , negative urine pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series ; Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period ; Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ; Any confirm suspected immunosuppressive immunodeficient condition result disease immunosuppressive/cytotoxic therapy ; History HZ ; Previous vaccination varicella HZ ; History allergic disease reaction likely exacerbate component vaccine . Additionally , consider allergic reaction material equipment relate study participation ; Significant underlie illness opinion investigator would expect prevent completion study ; Receipt immunoglobulins and/or blood product within 90 day precede first dose study vaccine plan administration study period ; Administration plan administration immunization within 30 day first second study vaccination schedule within 30 day study vaccination . However , license nonreplicating vaccine may administer 8 day prior dose and/or least 14 day dose study vaccine ; Any condition , opinion investigator , might interfere evaluation require study ; Acute disease and/or fever time enrollment ; Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Pregnant lactate female ; Female planning become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>subject 50 year old</keyword>
	<keyword>vaccine</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>efficacy</keyword>
	<keyword>Herpes Zoster</keyword>
	<keyword>safety</keyword>
</DOC>